Comparison of different assays for von Willebrand factor in hemodialysis patients

Haemostasis

Volumn 30, Issue 6, 2000, Pages 308-315

  Borawski, Jacek ^a   Pawlak, Krystyna ^a   Myśliwiec, Michał ^a,b  

^a Dept of Nephrology and Int Med ^*  (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Erythropoietin; Hemodialysis; Ristocetin induced platelet aggregation; Von Willebrand factor

Indexed keywords

GLYCOPROTEIN IB; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RISTOCETIN; VON WILLEBRAND FACTOR;

ADULT; ANEMIA; ARTICLE; ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; UREMIA;

EID: 0034445028     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054148     Document Type: Article

References (35)

1. Ruggeri ZM: Structure and function of von Willebrand factor. Thromb Haemost 1999;82(suppl 2):576-584.
2. Matsushita T, Sadler JE: Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1995;270:13406-13414.
3. Christophe O, Rouault C, Obert B, Pietu G, Meyer D, Girma JP: A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol 1995;90:1195-1199.
4. Azuma H, Hayashi T, Dent JA, Ruggeri ZM, Ware J: Disulfide bond requirements for assembly of the platelet membrane glycoprotein Ib binding domain of von Willebrand factor. J Biol Chem 1993;268:2821-2827.
5. Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH: Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997;78:1272-1277.
6. Fischer BE, Thomas KB, Dorner F: Von Willebrand factor: Measuring its antigen or function? Correlation between the level of antigen, activity and multimer size using various detection systems. Thromb Res 1998; 91:39-43.
7. Born GVR: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;94: 927-929.
8. 1 on human platelet aggregation in whole blood in vitro. J Pharm Pharmacol 1985;371:139-141.
9. Gris J-C, Branger B, Vecina F, Al-Sabdani B, Fourcade J, Schved J-F: Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46:807-813.
10. Ozsoylu S, Gürsel T: von Willebrand factor and rise in ristocetin co-factor with erythropoietin. Lancet 1993;341:1221.
11. Zwaginga JJ, Ijsseldijk MJ, Beeser-Visser N, de Groot PG, Sixma JJ: High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 1990;75:1498-1508.
12. Huraib S, Al-Momen AK, Gader AMA, Mitwalli A, Sulimani F, Abu-Aisha H: Effect of recombinant human erythropoietin (rHuEpO) on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 1991;36:252-257.
13. Johnson WJ, McCarthy JT, Yanagihara I, Osmundson PJ, Ilstrup DM, Jenson BM, Bowie EJW: Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. Kidney Int 1990;38:919-924.
14. Taylor JE, Belch JJF, McLaren M, Stewart WK: Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin. Blood Coagul Fibrinolysis 1995;6:100-104.
15. Mezzano D, Tagle R, Panes O, Perez M, Downey P, Munoz B, Aranda E, Barja P, Thambo S, Gonzalez F, Mezzano S, Pereira J: Hemostatic disorder of uremia: The platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 1996;76:312-321.
16. Mezzano D, Tagle R, Pais E, Panes O, Perez M, Downey P, Munoz B, Aranda E, Barja P, Thambo S, Gonzalez F, Mezzano S, Pereira J: Endothelial cell markers in chronic uremia: Relationship with hemostatic defects and severity of renal failure. Thromb Res 1997;88:465-472.
17. Van Geet C, Hauglustaine D, Verresen L, Vanrusselt M, Vermylen J: Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 1989;61:117-121.
18. Van Geet C, van Damme-Lombaerts R, Vanrusselt M, de Mol A, Proesmans W, Vermylen J: Recombinant human erythropoetin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: A possible link? Thromb Haemost 1990;64:7-10.
19. Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, Castillo R: Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992;42:668-672.
20. Gralnick HR, McKeown LP, Williams SB, Shafer B: Plasma and platelet von Willebrand factor defects in uremia. Am J Med 1988;85: 806-810.
21. Mannucci PM, Remuzzi G, Pusineri F, Lombardi F, Valsecchi C, Mecca G, Zimmerman TS: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12.
22. Escolar G, Cases A, Bastida E, Garrido M, Lopez J, Revert L, Castillo R, Ordinas A: Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990;76:13346-1340.
23. Sreedhara R, Itagaki I, Hakim RM: Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996;27:355-364.
24. Sloand EM, Sloand JA, Prodouz K, Klein HG, Yu MW, Harvath L, Fricke W: Reduction of glycoprotein Ib in uraemia. Br J Haematol 1991; 77:375-381.
25. Komarnicki M, Kazmierczak M, de Mezer-Dambek M: Binding of monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa in uremic patients. Nephron 1997;75: 283-288.
26. Vosburgh E, Bernard DB, Weinstein MJ: Absence of high molecular weight von Willebrand factor before and after hemodialysis despite a decrease in bleeding time. Blood 1989; 74(suppl 1):294.
27. Castaman G, Rodeghiero F, Lattuada A, La Greca G, Mannucci PM: Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol 1993;44:266-269.
28. Zwaginga JJ; Ijsseldijk MJW, de Groot PG, Kooistra M, Vos J, van Es A, Koomans HA, Struyvenberg A, Sixma JJ: Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemost 1991;66:638-647.
29. Gordge MP, Leaker B, Patel A, Cameron JS, Neild GH: Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation. Thromb Res 1990;57:171-182.
30. Moia M, Vizzotto L, Cattanco M, Mannucci PM, Casati S, Ponticelli C: Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987;28:1227-1229
31. Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, Buczko W, Mysliwiec M: A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995; 77:33-43.
32. Aunsholt NA, Steffensen G, Ahlbom G: Influence of recombinant human erythropoietin on platelet function and coagulation factors. Blood Purif 1992;10:248-253.
33. Liani M, Salvati F, Nubile G, Tresca E, Velussi C, Midrio M: von Willebrand factor and rise in ristocetin co-factor with erythropoietin. Lancet 1993;341:1221.
34. Borawski J, Rydzewski A, Azzadin A, Buczko W, Mysliwiec M: Modulation of hematopoiesis by ketanserin in erythropoietin-treated uremic patients: Evidence from platelet studies. Platelets 1998;9:31-35.
35. Borawski J, Rydzewski A, Pawlak K, Azzadin A, Buczko W, Mysliwiec M: Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment. Thromb Res 1998;90: 171-180.